Deferasirox (CAS 201530-41-8)
See product citations (9)
QUICK LINKS
Deferasirox is a tridentate iron chelator that binds iron with high affinity in a 2:1 ratio. Deferasirox has synergy with gemcitabine together they can reduce tumor growth and reduce proliferation of cancer cells. The binding properties of compounds like deferasirox can inspire the development of technologies for water purification and the remediation of environments contaminated with heavy metals. The ability of such compounds to selectively chelate metal ions can be harnessed in creating filtration systems or treatment processes that reduce metal ion concentrations in industrial effluents, thereby mitigating environmental pollution. Research into how deferasirox binds to iron can provide insights into the design of new compounds with improved specificity or affinity for certain metal ions, which can be applied in various industrial processes, including catalysis, material science, and nanotechnology.
Deferasirox (CAS 201530-41-8) References
- The iron chelator deferasirox protects mice from mucormycosis through iron starvation. | Ibrahim, AS., et al. 2007. J Clin Invest. 117: 2649-57. PMID: 17786247
- In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. | Berellini, G., et al. 2009. J Med Chem. 52: 4488-95. PMID: 19603833
- Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. | Messa, E., et al. 2010. Haematologica. 95: 1308-16. PMID: 20534700
- The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells. | Tataranni, T., et al. 2015. Br J Haematol. 170: 236-46. PMID: 25825160
- Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. | Martin-Sanchez, D., et al. 2017. Sci Rep. 7: 41510. PMID: 28139717
- Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy. | Salehi, S., et al. 2017. Toxicol Res. 33: 299-304. PMID: 29071014
- Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth. | Dai, L., et al. 2018. J Cancer. 9: 4503-4509. PMID: 30519356
- Emerging pharmaceuticals and industrial chemicals in Nakdong River, Korea: Identification, quantitative monitoring, and prioritization. | Park, N. and Jeon, J. 2021. Chemosphere. 263: 128014. PMID: 33297041
- Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats. | Rahdar, A., et al. 2021. Life Sci. 270: 119146. PMID: 33545199
- Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria. | Halloy, F., et al. 2021. Cell Chem Biol. 28: 1221-1234.e6. PMID: 33756123
- M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer. | Zhao, Y., et al. 2021. Pharmaceutics. 13: PMID: 34575569
- Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation. | Seike, K., et al. 2023. Immunity. 56: 353-368.e6. PMID: 36736321
- Iron bioavailability regulates Pseudomonas aeruginosa interspecies interactions through type VI secretion expression. | Haas, AL., et al. 2023. Cell Rep. 42: 112270. PMID: 36930643
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Deferasirox, 2.5 mg | sc-207509 | 2.5 mg | $180.00 |